Category Archives: Oncology

Inclusig Ponatinib Drug Safety Communication

Share

Inclusig (Ponatinib): Drug Safety Communication – Increased Reports Of Serious Blood Clots In Arteries And Veins AUDIENCE: Health Professional, Oncology ISSUE: FDA is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood … Continue reading

Share
Posted in FDA 2013, FDA Safety Communication, Healthcare Professionals, Oncology | Tagged , , , , , , , , | Comments Off on Inclusig Ponatinib Drug Safety Communication

Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT): Recall

Share

Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT): Recall – Concerns With Instructions For Use,  Promotional Claims and FDA Clearance AUDIENCE: Health Professional, Oncology ISSUE: Atossa Genetics Inc. initiated a voluntary recall to remove the ForeCYTE Breast … Continue reading

Share
Posted in FDA 2013, FDA Recall, Healthcare Professionals, Oncology | Tagged , , , , , , , , , , , | Comments Off on Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT): Recall

Arzerra ofatumumab and Rituxan rituximab Drug Safety Communication

Share

Arzerra (ofatumumab) and Rituxan (rituximab): Drug Safety Communication – New Boxed Warning, Recommendations to Decrease Risk of Hepatitis B Reactivation AUDIENCE: Oncology, Pharmacy, Rheumatology, Patient ISSUE: FDA approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra … Continue reading

Share
Posted in FDA 2013, FDA Safety Communication, Oncology, Patients, Pharmacy, Rheumatology | Tagged , , , , , , , , , , , , , , | Comments Off on Arzerra ofatumumab and Rituxan rituximab Drug Safety Communication

Kadcyla ado-trastuzumab emtansine Drug Safety Communication

Share

Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication – Potential Medication Errors Resulting from Name Confusion AUDIENCE: Risk Manager, Pharmacy, Oncology ISSUE: The FDA notified health care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla … Continue reading

Share
Posted in Oncology, Pharmacy, Risk Manager | Tagged , , , , , , , , , , | Comments Off on Kadcyla ado-trastuzumab emtansine Drug Safety Communication

Incretin Mimetic Drugs for Type 2 Diabetes

Share

Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas    AUDIENCE: Gastroenterology, Endocrinology, Oncology, Patient ISSUE: FDA is evaluating unpublished new findings by a group of … Continue reading

Share
Posted in Endocrinology, FDA 2013, FDA Warning, Gastroenterology, Oncology, Patients | Tagged , , , , , , , , | Comments Off on Incretin Mimetic Drugs for Type 2 Diabetes

Ondansetron Zofran IV Dose Safety Communication

Share

Ondansetron (Zofran) 32 mg, Single Intravenous (IV) Dose: Updated Safety Communication – Product Removal due to  Potential For Serious Cardiac Risks AUDIENCE: Oncology, Surgery, Health Professional ISSUE: FDA is notifying health care professionals that the 32 mg, single intravenous (IV) … Continue reading

Share
Posted in FDA 2012, FDA Safety Communication, Healthcare Professionals, Oncology, Surgery | Tagged , , , , , , , , , , , | Comments Off on Ondansetron Zofran IV Dose Safety Communication

Leucovorin Calcium Injection Bedford Laboratories Recall

Share

Leucovorin Calcium Injection (Bedford Laboratories): Recall – Visible Particulate Matter AUDIENCE: Pharmacy, Risk Manager, Oncology ISSUE: Bedford Laboratories issued a nationwide recall of three lots of Leucovorin Calcium Injection, due to the discovery of visible crystalline particulate matter in a … Continue reading

Share
Posted in FDA 2012, FDA Recall, Oncology, Pharmacy, Risk Manager | Tagged , , , , , , , , | Comments Off on Leucovorin Calcium Injection Bedford Laboratories Recall

Ondansetron Zofran IV Drug Safety Communication QT prolongation

Share

Ondansetron (Zofran) IV: Drug Safety Communication – QT prolongation AUDIENCE: Oncology, Surgery, Gastroenterology ISSUE: The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a … Continue reading

Share
Posted in FDA 2012, FDA Safety Communication, Gastroenterology, Oncology, Surgery | Tagged , , , , , , , , , | Comments Off on Ondansetron Zofran IV Drug Safety Communication QT prolongation

Altuzan bevacizumab Counterfeit Product

Share

Altuzan (bevacizumab): Counterfeit Product – Contains no Active Ingredient   ISSUE: FDA lab tests have confirmed that a counterfeit version of Roche’s Altuzan 400mg/16ml (bevacizumab),an injectable cancer medication, found in the U.S. contains no active ingredient. Even if the identified … Continue reading

Share
Posted in Family Practice, FDA 2012, FDA Recall, FDA Warning, Healthcare Professionals, Oncology, Patients | Tagged , , , , , , , , , , , , , , , , | Comments Off on Altuzan bevacizumab Counterfeit Product

Avastin bevacizumab Counterfeit Product

Share

Avastin (bevacizumab): Counterfeit Product – FDA Issues Letters to 19 Medical Practices AUDIENCE: Oncology, Pharmacy, Patient ISSUE: The FDA is warning healthcare professionals and patients about a counterfeit version of Avastin 400mg/16mL, which may have been purchased and used by … Continue reading

Share
Posted in FDA 2012, FDA Warning, Oncology, Pharmacy | Tagged , , , , , , , , , , , , | Comments Off on Avastin bevacizumab Counterfeit Product